PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...

The authors say there has been a recent uptick in hosptial admissions from hypoglycemic events, and that a therapy to address this is needed. A review of 15 studies has found that insulin degludec, ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky for those with type 1 diabetes, the phase III QWINT-2 and -5 trials showed.

ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...

This material is intended for UK medical media only. For journalistic assessment and preparation before publication. New findings show that Xultophy® (insulin degludec/liraglutide; IDegLira), the ...

Results showed treatment with insulin efsitora was noninferior to insulin degludac based on reduction in HbA1c at 52 weeks. Once-weekly insulin efsitora was found to be as effective as daily basal ...

Please provide your email address to receive an email when new articles are posted on . Women with type 1 diabetes who used insulin degludec during pregnancy had similar HbA1c and glucose profile as ...

Please provide your email address to receive an email when new articles are posted on . Insulin efsitora alfa conferred noninferior HbA1c reductions vs. insulin degludec in two phase 3 trials. Level ...

Most types of insulin therapy, an important part of diabetes treatment for many people, are given as daily injections to help manage blood sugar levels. Now, the maker of a once-weekly insulin ...

MADRID — Eli Lilly's investigational once-weekly basal insulin analog efsitora alfa continues to show noninferiority to once-daily insulin in people with type 2 diabetes. However, in those with type 1 ...